Table 2.
Design of CRF antagonist experiments
| Dorsal raphe pre-infusion | Dorsal raphe infusion | N |
|---|---|---|
| Vehicle (0.5 μL) | CRF (0.5 μg/0.5 μL) | 6 |
| ASV-30 (2 μg/0.5 μL) | CRF (0.5 μg/0.5 μL) | 6 |
| Vehicle (0.5 μL) | CRF (0.5 μg/0.5 μL) | 6 |
| Antalarmin (25 ng/0.5 μL) | CRF (0.5 μg/0.5 μL) | 6 |
| Antalarmin (50 ng/0.5 μL) | CRF (0.5 μg/0.5 μL) | 4 |